THE SAFETY AND EFFICACY OF VIRAMIDINE® PLUS PEGYLATED INTERFERON ALFA-2B VERSUS RIBAVIRIN PLUS PEGYLATED INTERFERON ALFA-2B IN THERAPY-NAÏVE PATIENTS INFECTED WITH HCV: PHASE 3 RESULTS
Y Benhamou. Abstract 751.

EARLY VIRAL RESPONSE TO CPG 10101, IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN, IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSE RESPONSE
J G McHutchison. Abstract 730

INTERIM RESULTS OF A MULTIPLE ASCENDING DOSE STUDY OF R1626, A NOVEL NUCLEOSIDE ANALOG TARGETING HCV POLYMERASE IN CHRONIC HCV PATIENTS
S Roberts. Abstract 731.

INTERIM (WEEK 12) PHASE 2B VIROLOGICAL EFFICACY AND SAFETY RESULTS OF ALBUMIN INTERFERON ALFA-2B COMBINED WITH RIBAVIRIN IN GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
S Zeuzem. Abstract 733.

PEGINTERFERON ALFA-2A (PEGASYS) PLUS RIBAVIRIN (COPEGUS) FOR 16 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3. FINAL RESULTS OF THE ACCELERATE TRIAL
M L Shiffman. Abstract 734.

Final Results of the REPEAT and ACCELERATE Trials of Peginterferon Alfa-2a (Pegasys)Plus Copegus (Ribavirin)
M L Shiffman. Abstract 734 (ACCELERATE TRIAL).
P Marcellin. Abstract 11 (REPEAT Trial).

EARLY CLEARANCE OF HCV RNA WITH VALOPICITABINE (NM283) PLUS PEG-INTERFERON IN TREATMENT-NAÏVE PATIENTS WITH HCV-1 INFECTION: FIRST RESULTS FROM A PHASE IIB TRIAL
D Dieterich. Abstract 736.

INITIAL RESULTS OF A 14-DAY STUDY OF THE HEPATITIS C VIRUS INHIBITOR PROTEASE VX-950, IN COMBINATION WITH PEGINTERFERON-ALFA-2A
HW Reesink. Abstract 737.

SUSTAINED VIROLOGIC RESPONSE (SVR) TO INTERFERON-ALFA-2B+/- RIBAVIRIN THERAPY AT 6 MONTHS RELIABLY PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR FOLLOW UP
J G McHutchison. Abstract 744.

A ONE YEAR RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF ROSIGLITAZONE IN NON ALCOHOLIC STEATOHEPATITIS: RESULTS OF THE FLIRT PILOT TRIAL
V Ratziu. Abstract 738.

EFFICACY AND SAFETY OF ELTROMBOPAG, AN ORAL PLATELET GROWTH FACTOR, IN SUBJECTS WITH HCV ASSOCIATED THROMBOCYTOPENIA: PRELIMINARY RESULTS FROM A PHASE II DOSE-RANGING STUDY
J G McHutchison. Abstract 745.

PRECLINICAL CHARACTERISTICS OF ITMN-B, AN ORALLY ACTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE NOMINATED FOR PRECLINICAL DEVELOPMENT
S D Seiwert. Abstract 750.

Treatment for Chronic Hepatitis B

THE MAJORITY OF PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) [PEGASYS®] SUSTAIN RESPONSES 2 YEARS POST-TREATMENT
P Marcellin. Abstract 743.

EMERGENCE OF DUAL-RESISTANCE HBV MUTATIONS TO ADEFOVIR-DIPIVOXIL AND LAMIVUDINE IN A HEPATITIS B PATIENT WITH COMBINATION THERAPY FOR ADEFOVIR-RESISTANCE
SY Kwon. Abstract 740.

EFFECT OF CORE PROMOTER/PRECORE MUTATION PATTERN AND EARLY VIROLOGIC RESPONSE ON EFFICACY OUTCOMES WITH TELBIVUDINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B
N Naoumov. Abstract 747.

SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF PRADEFOVIR MESYLATE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION: 48-WEEK ANALYSIS OF A PHASE 2 STUDY
K S Lee. Abstract 741.

A NOVEL PRIMEBOOST THERAPEUTIC VACCINE INDUCES SUSTAINED SEROCONVERSION AT 52 WEEKS IN PATIENTS WITH HBEAG+ CHRONIC HEPATITIS B: A PHASE IIA CLINICAL TRIAL
J Schneider. Abstract 749.